Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Net Cash Flow (2020 - 2025)

Maxcyte (MXCT) has disclosed Net Cash Flow for 6 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 178.16% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.8 million through Dec 2025, up 58.01% year-over-year, with the annual reading at -$7.8 million for FY2025, 58.01% up from the prior year.
  • Net Cash Flow for Q4 2025 was $7.1 million at Maxcyte, up from -$2.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $192.0 million in Q1 2022, with the low at -$130.6 million in Q2 2022.
  • Average Net Cash Flow over 5 years is $65460.0, with a median of -$3.6 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 225.15% in 2021, while the deepest fall reached 409.24% in 2021.
  • Over 5 years, Net Cash Flow stood at -$11.2 million in 2021, then tumbled by 185.55% to -$32.0 million in 2022, then soared by 91.66% to -$2.7 million in 2023, then crashed by 240.49% to -$9.1 million in 2024, then soared by 178.16% to $7.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $7.1 million, -$2.3 million, and -$8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.